# Quantum BioPharma Lucid-MS development > Live situation record from CLSTR: https://clstr.news/situations/quantum-biopharma-lucid-ms-development > Updated: 2026-09-23T17:29:41.000Z. Sources: 5. Developments: 2. Quantum BioPharma is developing Lucid-MS, an investigational drug candidate designed to treat multiple sclerosis (MS) by directly inhibiting demyelination. The treatment targets the enzyme peptidyl arginine deiminase 2 (PAD2) to address nerve damage, rather than focusing on immune system suppression like many current therapies. Following the completion of Phase 1 trials, which indicated a favorable safety profile, the company has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with Phase 2 clinical testing. This phase aims to evaluate the drug’s ability to protect and repair the myelin sheath. While medical experts view this as a significant shift toward myelin-repair therapy, its ability to reverse existing disability remains uncertain. The development comes amid a global MS patient population of approximately 2.9 million, with nearly one million people living with the condition in the United States. Current approved therapies often fail to reverse the neurodegeneration that leads to long-term disability, highlighting the potential need for approaches like Lucid-MS. ## Timeline ### 2026-09-23: Quantum BioPharma receives FDA clearance for Lucid-MS Phase 2 trials Quantum BioPharma has received FDA clearance to begin Phase 2 clinical trials for Lucid-MS, a drug candidate designed to target demyelination in multiple sclerosis patients. 3 sources. https://clstr.news/cluster/quantum-biopharma-develops-lucid-ms-for-multiple-sclerosis ### 2026-09-09: Quantum Biopharma receives FDA clearance for MS myelin-repair drug trial Quantum Biopharma's Lucid-MS has cleared FDA hurdles for phase two trials to target myelin repair, while new research shows B-cell therapies may reduce MS relapses and MRI lesions more effectively than orals. 2 sources. https://clstr.news/cluster/quantum-biopharma-receives-fda-clearance-for-ms-myelin-repair-drug-trial --- Cite as: Quantum BioPharma Lucid-MS development. CLSTR, https://clstr.news/situations/quantum-biopharma-lucid-ms-development